Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.